Antitrust regulators say companies seeking approval for big deals are flooding them with what they see as being questionable economic analyses. (Photo: Thinkstock)

(Bloomberg) —The Justice Department is sending a warning signal to health insurers, chemical companies and others seeking antitrust approval for big deals: Leave the dubious charts at home.

Antitrust lawyers for companies seeking approval for big mergers have for years bolstered their case by providing extensive economic analyses, often market by market, to show that the tie-ups wouldn’t stifle competition. Now, Justice Department officials are saying they’re not going to be swayed in their analysis by impenetrable economic models.

Related: Researchers: Cross-market hospital deals also raise prices 

While the Justice Department isn’t naming names or pointing any fingers for presenting unseemly data, the comments are the most recent indication that it’s taking a tougher stance against megadeals. The latest salvo came Thursday, when the department’s No. 3 official, Bill Baer, said antitrust enforcers can’t let up on their commitment to blocking mergers that the department deems anticompetitive in the waning days of the Obama administration.

“Our assessments of competitive effects do not simply rely on quantitative evidence provided by expert testimony,” Baer, who until recently ran the department’s antitrust unit, said in a speech in Washington. Company documents and testimony from rivals and consumers may provide better evidence, he said.

‘Junk science’

“Junk science” is what another official, David Gelfand, called some of the economic analysis presented to the department to justify deals. Charts and pictures are great — but not data that’s mixed and matched to make a case, Gelfand said in a June 6 speech in Washington, shortly before leaving his job as a deputy assistant attorney general in charge of litigation to return to private practice.

U.S. antitrust enforcers who have recently opposed deals to unite office suppliers, oil-services firms and cable companies, are now vetting mergers that could remake agriculture and health care.

Related: Hospital group: “Remedies” for insurer deal market effects are quackery

“The United States is in the midst of a merger wave, with the number, size and complexity of mergers among the highest they have been in the last decade,” said Baer, who is now the Justice Department’s acting associate attorney general. “Especially in this environment, we cannot afford to let up our efforts.”

Close scrutiny

Planned mergers among four of the five biggest U.S. health insurers and agricultural chemical and seed companies would lead to “substantial consolidation” and require close scrutiny, Baer said.

The antitrust division is now reviewing efforts by Indianapolis-based Anthem to acquire Bloomfield, Connecticut-based Cigna Corp. and efforts by Hartford, Connecticut-based Aetna Inc. to acquire Louisville, Kentucky-based Humana. Those mergers could reduce the number of major U.S. health insurers to three, from five. Baer has previously called them a “game changer.”

Related: California insurance regulator tells U.S. to block Anthem-Cigna deal

The division is also reviewing other large deals outside the health insurance market.

Gelfand, in his remarks earlier this month, criticized some of the economic evidence presented to the division during his tenure. He urged economists, who are often called as expert witnesses in merger trials, to dispense with jargon and present clear arguments that are supported by data.

“You need to be able to explain in simple terms the nature of the work you have done, the source of the information that feeds into that work, and why it demonstrates the point you are trying to make,” Gelfand said in the speech. “It is not persuasive to rattle off technical jargon and expect us to take on faith that a conclusion is valid simply because you obtained some value for a statistic.”

Gelfand cited one study that purported to show that a previous merger in the industry had no effect on prices although the underlying data showed prices for the products at issue did rise, a result that was omitted from the report, he said. The price data “should have been disclosed and presented with candor,” Gelfand said. That transaction was ultimately abandoned, he added.

Related: 

Health insurer deals face market review that felled past tie-ups

U.S. antitrust watchdogs turn to insurers after Halliburton win

 

Have you followed us on Facebook?

Copyright 2018 Bloomberg. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.